GHRH 1-44 Reference

Plain English

What it is

GHRH 1-44 is the full-length version of a natural body signal called growth hormone-releasing hormone, which tells the pituitary gland to make and release its own growth hormone. The well-known peptide sermorelin is just the first 29 building blocks of this same hormone. GHRH 1-44 is sold as a research chemical and is not FDA-approved. There is no approved GHRH 1-44 product, and sermorelin's old brand Geref was approved years ago and then pulled from the US market.

What people use it for

In peptide communities people use it to try to nudge the body into releasing more of its own growth hormone. Because it is the full-length parent of sermorelin, some prefer it for completeness. Most online discussion still centers on sermorelin or CJC-1295 because more is written about them, so GHRH 1-44 stays a niche choice.

What the science shows

Most human research is older and small, using a single injection of GHRH 1-44 as a check to see how the pituitary responds and to tell apart whether a growth hormone shortage comes from the hypothalamus or the pituitary. There is no modern program showing long-term results or safety for using it as a research peptide.

The catch

It is not FDA-approved. Growth hormone and its releasing factors, including GHRH and its analogues, are banned in sport at all times by the World Anti-Doping Agency. Quality, purity, and content of research-chemical peptides are not verified by any regulator.

Reference summary

Older human GH-provocative-test literature exists for GHRH 1-44. Modern outcome programs are limited; current community use extrapolates from the broader GHRH-analog class.

Regulatory and posture

Categories

GH Release

Aliases

Growth hormone-releasing hormone (full length), Somatorelin, Somatocrinin

Evidence posture

human - Older small human GH-provocative-test studies dominate the literature. No modern PK/PD or outcome program is established for full-length GHRH 1-44 as a research peptide.

Regulatory status

No FDA-approved GHRH 1-44 drug label currently on the US market. Sermorelin (GHRH 1-29) was previously FDA-approved as Geref but withdrawn; full-length GHRH 1-44 is not currently approved as a stand-alone product in the United States.

Content review status

research reference

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• Injection-site rotation overview - Public overview of the Pro site-rotation planner.